Generation and functional characterization of MDSC-like cells
Annkristin Heine1, Stefanie Andrea Erika Held1, Jonas Schulte-Schrepping2
1Medical Clinic III for Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany.
Oncoimmunology
|May 17, 2017
Summary
Myeloid-derived suppressor cells (MDSC) suppress T cell responses by increasing osteoactivin/syndecan-4 and PD-1/PD-L1. Inhibiting these molecules restores dendritic cell function, offering potential clinical applications.
Area of Science:
- Immunology
- Cell Biology
Background:
- Myeloid-derived suppressor cells (MDSC) are crucial regulators of immune responses, inhibiting antigen-presenting cells (APC) and T cells.
- Interleukin-10 (IL-10) differentiation of monocytes generates IL-10-APC, a population with characteristics similar to human MDSC.
Purpose of the Study:
- To investigate the mechanisms by which IL-10-induced APCs (IL-10-APC) and human MDSC suppress dendritic cell (DC) function.
- To identify key molecules involved in MDSC-mediated immune suppression for potential therapeutic targeting.
Main Methods:
- Co-incubation of IL-10-APC with monocyte-derived dendritic cells (moDC) to assess effects on T cell proliferation, maturation markers, and cytokine/chemokine secretion.
- Transcriptome analysis to identify molecular pathways involved in MDSC function.
- Use of blocking antibodies against osteoactivin, syndecan-4, PD-1, and PD-L1 to evaluate their role in MDSC-mediated inhibition.
- Activation of MDSC with Dectin-1 ligand curdlan to assess its impact on immunosuppressive molecule expression.
Main Results:
- IL-10-APC addition to moDC reduced T cell proliferation, DC maturation markers, and suppressed key cytokines/chemokines.
- IL-10-APC and human MDSC exhibited increased expression of osteoactivin/syndecan-4 and PD-1/PD-L1.
- Inhibition of osteoactivin, syndecan-4, PD-1, or PD-L1 restored DC stimulatory capacity.
- Curdlan treatment of MDSC decreased osteoactivin and PD-L1 expression.
Conclusions:
- Osteoactivin/syndecan-4 and PD-1/PD-L1 pathways are critical mediators of MDSC-induced inhibition of DC function.
- Targeting these molecules presents a promising strategy for modulating immune responses in clinical settings.


